Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis

Science Translational Medicine

Volumn 8, Issue 344, 2016, Pages

  Dekkers, Johanna F ^a   Berkers, Gitte ^a   Kruisselbrink, Evelien ^a   Vonk, Annelotte ^a   De Jonge, Hugo R ^b   Janssens, Hettie M ^c   Bronsveld, Inez ^d   Van De Graaf, Eduard A ^d   Nieuwenhuis, Edward E S ^a   Houwen, Roderick H J ^a   Vleggaar, Frank P ^d   Escher, Johanna C ^c   De Rijke, Yolanda B ^c   Majoor, Christof J ^e   Heijerman, Harry G M ^f   De Winter De Groot, Karin M ^a   Clevers, Hans ^d   Van Der Ent, Cornelis K ^a   Beekman, Jeffrey M ^a,d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f HAGA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FORSKOLIN; IVACAFTOR; LUMACAFTOR; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPHENOL DERIVATIVE; AMINOPYRIDINE DERIVATIVE; CFTR PROTEIN, HUMAN; CHLORIDE; QUINOLONE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG RESPONSE; FORCED EXPIRATORY VOLUME; GENE MUTATION; GENETIC BACKGROUND; HOMOZYGOTE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECTUM; BIOASSAY; DRUG EFFECTS; GENETICS; GENOTYPE; METABOLISM; MUTATION; ORGANOID; PROCEDURES;

AMINOPHENOLS; AMINOPYRIDINES; BENZODIOXOLES; BIOLOGICAL ASSAY; CHLORIDES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENOTYPE; HUMANS; IN VITRO TECHNIQUES; MUTATION; ORGANOIDS; QUINOLONES;

EID: 84975464759     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aad8278     Document Type: Article

References (44)

1. S. C. Bell, K. De Boeck, M. D. Amaral, New pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls. Pharmacol. Ther. 145, 19-34 (2015).
2. P. R. Sosnay, K. R. Siklosi, F. Van Goor, K. Kaniecki, H. Yu, N. Sharma, A. S. Ramalho, M. D. Amaral, R.Dorfman, J. Zielenski, D. L. Masica, R. Karchin, L. Millen, P. J. Thomas, G. P. Patrinos, M. Corey, M. H. Lewis, J. M. Rommens, C. Castellani, C. M. Penland, G. R. Cutting, Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat. Genet. 45, 1160-1167 (2013).
3. G. R. Cutting, Cystic fibrosis genetics: From molecular understanding to clinical application. Nat. Rev. Genet. 16, 45-56 (2015).
4. B. W. Ramsey, J. Davies, N. G. McElvaney, E. Tullis, S. C. Bell, P. Dřevínek, M. Griese, E. F. McKone, C. E. Wainwright, M. W. Konstan, R. Moss, F. Ratjen, I. Sermet-Gaudelus, S. M. Rowe, Q. Dong, S. Rodriguez, K. Yen, C. Ordoñez, J. S. Elborn; VX08-770-102 Study Group, A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365, 1663-1672 (2011).
5. F. J. Accurso, S. M. Rowe, J. P. Clancy, M. P. Boyle, J. M. Dunitz, P. R. Durie, S. D. Sagel, D. B. Hornick, M. W. Konstan, S. H. Donaldson, R. B. Moss, J. M. Pilewski, R. C. Rubenstein, A. Z. Uluer, M. L. Aitken, S. D. Freedman, L. M. Rose, N. Mayer-Hamblett, Q. Dong, J. Zha, A. J. Stone, E. R. Olson, C. L. Ordoñez, P. W. Campbell, M. A. Ashlock, B. W. Ramsey, Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N. Engl. J. Med. 363, 1991-2003 (2010).
6. K. De Boeck, A. Munck, S. Walker, A. Faro, P. Hiatt, G. Gilmartin, M. Higgins, Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J. Cyst. Fibros. 13, 674-680 (2014).
7. M. P. Boyle, S. C. Bell, M. W. Konstan, S. A. McColley, S. M. Rowe, E. Rietschel, X. Huang, D. Waltz, N. R. Patel, D. Rodman; VX09-809-102 study group, A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial. Lancet Respir. Med. 2, 527-538 (2014).
8. C. E. Wainwright, J. S. Elborn, B. W. Ramsey, G. Marigowda, X. Huang, M. Cipolli, C. Colombo, J. C. Davies, K. De Boeck, P. A. Flume, M. W. Konstan, S. A. McColley, K. McCoy, E. F. McKone, A. Munck, F. Ratjen, S. M. Rowe, D. Waltz, M. P. Boyle; TRAFFIC and TRANSPORT Study Groups, Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N. Engl. J. Med. 373, 220-231 (2015).
9. T. Sato, D. E. Stange, M. Ferrante, R. G. J. Vries, J. H. van Es, S. van den Brink, W. J. van Houdt, A. Pronk, J. van Gorp, P. D. Siersema, H. Clevers, Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 141, 1762-1772 (2011).
10. T. Sato, H. Clevers, Growing self-organizing mini-guts from a single intestinal stem cell: Mechanism and applications. Science 340, 1190-1194 (2013).
11. J. F. Dekkers, C. K. van der Ent, J. M. Beekman, Novel opportunities for CFTR-targeting drug development using organoids. Rare Dis. 1, e27112 (2013).
12. J. F. Dekkers, C. L. Wiegerinck, H. R. de Jonge, I. Bronsveld, H. M. Janssens, K. M. de Winter-de Groot, A. M. Brandsma, N. W. M. de Jong, M. J. C. Bijvelds, B. J. Scholte, E. E. S. Nieuwenhuis, S. van den Brink, H. Clevers, C. K. van der Ent, S. Middendorp, J. M. Beekman, A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat. Med. 19, 939-945 (2013).
13. T. Okiyoneda, G. Veit, J. F. Dekkers, M. Bagdany, N. Soya, H. Xu, A. Roldan, A. S. Verkman, M. Kurth, A. Simon, T. Hegedus, J. M. Beekman, G. L. Lukacs, Mechanism-based corrector combination restores DF508-CFTR folding and function. Nat. Chem. Biol. 9, 444-454 (2013).
14. J. Foulke-Abel, J. In, J. Yin, N. C. Zachos, O. Kovbasnjuk, M. K. Estes, H. de Jonge, M. Donowitz, Human enteroids as a model of upper small intestinal Ion transport physiology and pathophysiology. Gastroenterology 150, 638-649.e8 (2016).
15. N. Derichs, J. Sanz, T. Von Kanel, C. Stolpe, A. Zapf, B. Tümmler, S. Gallati, M. Ballmann, Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: Validation and reference data. Thorax 65, 594-599 (2010).
16. - secretion in human rectal biopsies constitute a robust biomarker for Cystic Fibrosis diagnosis and prognosis. PLOS One 7, e47708 (2012).
17. M. Mall, S. Hirtz, T. Gonska, K. Kunzelmann, Assessment of CFTR function in rectal biopsies for the diagnosis of cystic fibrosis. J. Cyst. Fibros. 3 (Suppl. 2), 165-169 (2004).
18. H. R. de Jonge, M. Ballmann, H. Veeze, I. Bronsveld, F. Stanke, B. Tümmler, M. Sinaasappel, Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers. J. Cyst. Fibros. 3 (Suppl. 2), 159-163 (2004)
19. H. Li, D. N. Sheppard, M. J. Hug, Transepithelial electrical measurements with the Ussing chamber. J. Cyst. Fibros. 3 (Suppl. 2), 123-126 (2004).
20. L. E. Gibson, R. E. Cooke, A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 23, 545-549 (1959).
21. P. M. Quinton, Chloride impermeability in cystic fibrosis. Nature 301, 421-422 (1983).
22. P. A. Flume, T. G. Liou, D. S. Borowitz, H. Li, K. Yen, C. L. Ordoñez, D. E. Geller; VX 08-770-104 Study Group, Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 142, 718-724 (2012).
23. J. P. Clancy, S. M. Rowe, F. J. Accurso, M. L. Aitken, R. S. Amin, M. A. Ashlock, M. Ballmann, M. P. Boyle, I. Bronsveld, P. W. Campbell, K. De Boeck, S. H. Donaldson, H. L. Dorkin, J. M. Dunitz, P. R. Durie, M. Jain, A. Leonard, K. S. McCoy, R. B. Moss, J. M. Pilewski, D. B. Rosenbluth, R. C. Rubenstein, M. S. Schechter, M. Botfield, C. L. Ordoñez, G. T. Spencer-Green, L. Vernillet, S. Wisseh, K. Yen, M. W. Konstan, Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67, 12-18 (2011).
24. Y. Uezono, J. Bradley, C. Min, N. A. McCarty, M. Quick, J. R. Riordan, C. Chavkin, K. Zinn, H. A. Lester, N. Davidson, Receptors that couple to 2 classes of G proteins increase cAMP and activate CFTR expressed in Xenopus oocytes. Recept. Channels 1, 233-241 (1993).
25. D.-J. Dijkstra, H. Scheffer, C. H. C. M. Buys, A novel mutation (G1249R) in exon 20 of the CFTR gene. Hum. Mutat. 4, 161-162 (1994).
26. F. Van Goor, H. Yu, B. Burton, B. J. Hoffman, Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J. Cyst. Fibros. 13, 29-36 (2014).
27. K.-H. Gan, H. J. Veeze, A. van den Ouweland, D. Halley, H. Scheffer, A. van der Hout, S. E. Overbeek, J. C. de Jongste, W. Bakker, H. G. Heijerman, A cystic fibrosis mutation associated with mild lung disease, N. Engl. J. Med. 333, 95-99 (1995).
28. E. F. McKone, S. S. Emerson, K. L. Edwards, M. L. Aitken, Effect of genotype on phenotype and mortality in cystic fibrosis: A retrospective cohort study. Lancet 361, 1671-1676 (2003).
29. G. Antiñolo, S. Borrego, M. Gili, J. Dapena, I. Alfageme, F. Reina, Genotype-phenotype relationship in 12 patients carrying cystic fibrosis mutation R334W. J. Med. Genet. 34, 89-91 (1997).
30. S. Middendorp, K. Schneeberger, C. L. Wiegerinck, M. Mokry, R. D. L. Akkerman, S. van Wijngaarden, H. Clevers, E. E. S. Nieuwenhuis, Adult stem cells in the small intestine are intrinsically programmed with their location-specific function. Stem Cells 32, 1083-1091 (2014).
31. M. Huch, H. Gehart, R. van Boxtel, K. Hamer, F. Blokzijl, M. M. A. Verstegen, E. Ellis, M. van Wenum, S. A. Fuchs, J. de Ligt, M. van de Wetering, N. Sasaki, S. J. Boers, H. Kemperman, J. de Jonge, J. N. M. Ijzermans, E. E. S. Nieuwenhuis, R. Hoekstra, S. Strom, R. R. G. Vries, L. J. W. van der Laan, E. Cuppen, H. Clevers, Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell 160, 299-312 (2015).
32. T. Sato, R. G. Vries, H. J. Snippert, M. van de Wetering, N. Barker, D. E. Stange, J. H. van Es, A. Abo, P. Kujala, P. J. Peters, H. Clevers, Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459, 262-265 (2009).
33. M. E. Wood, D. J. Smith, D. W. Reid, P. J. Masel, M. W. France, S. C. Bell, Ivacaftor in severe cystic fibrosis lung disease and a G551D mutation. Respirol. Case Rep. 1, 52-54 (2013).
34. H. G. M. Arets, H. J. L. Brackel, C. K. van der Ent, Applicability of interrupter resistance measurements using the MicroRint® in daily practice. Respir. Med. 97, 366-374 (2003).
35. A. Rocha, M. V. F. Donadio, D. V. de Ávila, P. X. Hommerding, P. J. C. Marostica, Using the interrupter technique to evaluate airway resistance in cystic fibrosis patients. J. Bras. Pneumol. 38, 188-193 (2012).
36. S. Sonnappa, C. M. Bastardo, A. Wade, A. Bush, J. Stocks, P. Aurora, Repeatability and bronchodilator reversibility of lung function in young children. Eur. Respir. J. 42, 116-124 (2013).
37. H. Yu, B. Burton, C.-J. Huang, J. Worley, D. Cao, J. P. Johnson Jr., A. Urrutia, J. Joubran, S. Seepersaud, K. Sussky, B. J. Hoffman, F. Van Goor, Ivacaftor potentiation of multiple CFTR channels with gating mutations. J. Cyst. Fibros. 11, 237-245 (2012).
38. D. M. Cholon, N. L. Quinney, M. L. Fulcher, C. R. Esther Jr., J. Das, N. V. Dokholyan, S. H. Randell, R. C. Boucher, M. Gentzsch, Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis. Sci. Transl. Med. 6, 246ra96 (2014).
39. G. Veit, R. G. Avramescu, D. Perdomo, P.-W. Phuan, M. Bagdany, P. M. Apaja, F. Borot, D. Szollosi, Y.-S. Wu, W. E. Finkbeiner, T. Hegedus, A. S. Verkman, G. L. Lukacs, Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression. Sci. Transl. Med. 6, 246ra97 (2014).
40. E. O. Lillie, B. Patay, J. Diamant, B. Issell, E. J. Topol, N. J. Schork, The n-of-1 clinical trial: The ultimate strategy for individualizing medicine? Pers. Med. 8, 161-173 (2011).
41. C. Vitzthum, W. G. Clauss, M. Fronius, Mechanosensitive activation of CFTR by increased cell volume and hydrostatic pressure but not shear stress. Biochim. Biophys. Acta 1848, 2942-2951 (2015).
42. + stem cells require SpiB and are induced by RankL in cultured "miniguts". Mol. Cell. Biol. 32, 3639-3647 (2012).
43. C. Moon, K. L. VanDussen, H. Miyoshi, T. S. Stappenbeck, Development of a primary mouse intestinal epithelial cell monolayer culture system to evaluate factors that modulate IgA transcytosis. Mucosal Immunol. 7, 818-828 (2014).
44. K. De Boeck, N. Derichs, I. Fajac, H. R. de Jonge, I. Bronsveld, I. Sermet, F. Vermeulen, D. N. Sheppard, H. Cuppens, M. Hug, P. Melotti, P. G. Middleton, M. Wilschanski, ECFS. Diagnostic Network Working Group; EuroCareCF WP3 Group on CF diagnosis, New clinical diagnostic procedures for cystic fibrosis in Europe. J. Cyst. Fibros. 10 (Suppl. 2), S53-S66 (2011).